Medtronic Rapid-Exchange Exit Contributes To 28% Decline In Vascular Sales
This article was originally published in The Gray Sheet
Executive Summary
A prolonged absence from the U.S. rapid-exchange delivery segment continues to encroach on Medtronic's once high-growth vascular intervention business unit
You may also be interested in...
Medtronic Drug-Eluting Stent Trial Aims For Equivalency, Approval In 2005
Medtronic's U.S. pivotal study of its rapamycin analog-eluting stent will randomize patients to Johnson & Johnson/Cordis' siroliumus-eluting Cypher in the control arm
Medtronic Drug-Eluting Stent Trial Aims For Equivalency, Approval In 2005
Medtronic's U.S. pivotal study of its rapamycin analog-eluting stent will randomize patients to Johnson & Johnson/Cordis' siroliumus-eluting Cypher in the control arm
Medtronic To Offer Vascular Access Closure System Under Scion Pact
Medtronic will distribute Scion Cardio-Vascular's Clo-Sur P.A.D. to control bleeding at vascular access sites under a Sept. 9 distribution agreement that includes a minority equity investment